KPTI

$8.38

Post-MarketAs of Mar 17, 8:00 PM UTC

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$8.38
Potential Upside
5%
Whystock Fair Value$8.80
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develop...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$153.72M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.20
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.98

Recent News

MarketBeat
Feb 24, 2026

Karyopharm Therapeutics Shareholders Approve Plan to Nearly Double Authorized Shares at Special Meeting

Karyopharm Therapeutics (NASDAQ:KPTI) held a virtual special meeting of stockholders on Feb. 18, 2026, to vote on two proposals outlined in the company’s proxy materials. The meeting was chaired by President, CEO, and Director Richard Paulson, with Chief Legal Officer Michael Mano serving as secreta

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Feb 18, 2026

Wall Street Analysts Believe Karyopharm Therapeutics (KPTI) Could Rally 56.06%: Here's is How to Trade

The consensus price target hints at a 56.1% upside potential for Karyopharm Therapeutics (KPTI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Feb 15, 2026

Analysts Have Made A Financial Statement On Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Annual Report

The investors in Karyopharm Therapeutics Inc. 's ( NASDAQ:KPTI ) will be rubbing their hands together with glee today...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Feb 12, 2026

Karyopharm Therapeutics Inc (KPTI) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst ...

Karyopharm Therapeutics Inc (KPTI) reports strong revenue growth and strategic advancements in myelofibrosis, despite facing financial hurdles and increased competition.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Feb 12, 2026

Karyopharm Therapeutics Q4 Earnings Call Highlights

Karyopharm Therapeutics (NASDAQ:KPTI) executives highlighted upcoming late-stage clinical catalysts, continued revenue growth for its multiple myeloma franchise, and a tighter cost structure during the company’s fourth-quarter and full-year 2025 earnings call. Management repeatedly pointed investor

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.